Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid™ and Tollovir™ Ingredients
Claims covering inhibition of 3CL protease, inflammation and autophagy underscore Dr. Dorit Arad’s lifelong work
NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, ISRAEL, Aug. 30, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Todos Medical, Ltd. (OTCQB:TOMDF), a medical diagnostics and related solutions company, today announced that the United States Patent & Trademark Office (USPTO) has issued a Notice of Allowance for NLC Pharma’s patent application entitled “Compounds for Treating a Coronavirus Infection” prosecuted from the groundbreaking work of Dr. Dorit Arad. The Notice of Allowance covers the use of key compounds contained in the ingredients in Tollovid™ and Tollovir™ (NLC-V-01, NLC-001 or 3CL-001). The allowed claims are directed, among other things, to the administration of compounds to a subject to inhibit activity of the 3CL protease, inflammation and autophagy, and to treat coronavirus infection.
Related news for (TOMDF)
- Todos Medical Announces Insolvency Proceedings in Israel
- Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic
- Todos Medical Enters Into Letter of Intent for Provista Diagnostics to License PCR-based Sepsis Diagnostic Test AcuSept LDT Rights From Acumen Diagnostics
- Todos Medical Begins Trading on the OTC Pink Marketplace